Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ULD-TSEBT and Brentuximab Vedotin in Mycosis Fungoides
NCT05357794Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2022
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in mycosis fungoides (MF), Sézary syndrome (SS), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2022; status: recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT05357794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05357794.